Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior …
WEB4 days ago · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study ...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior …
WEB4 days ago · WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty ® for ...
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's …
WEB3 days ago · Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty. ... Following the news, the stock gained 5. ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine …
WEB4 days ago · CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer ...
Unveiling 3 Analyst Insights On Arcturus Therapeutics
WEB3 days ago · Analysts have set 12-month price targets for Arcturus Therapeutics, revealing an average target of $65.33, a high estimate of $70.00, and a low estimate of $63.00. This current average reflects an ...
Arcturus Therapeutics: Buy Rating Affirmed Amid Kostaive Launch …
WEBAug 7, 2024 · Ed Arce has given his Buy rating due to a combination of factors including the imminent commercial launch of Kostaive in Japan and the financial benefits it brings to Arcturus Therapeutics.
New COVID Variant Arcturus XBB.1.16, Explained - TODAY
WEBApr 26, 2023 · The XBB.1.16 Omicron subvariant is increasing, with anecdotal reports that it may be causing some unusual symptoms like pink eye. Here's what you need to know. April 26, 2023, 10:09 AM PDT ...
Arcturus Announces Collaboration with CSL to Develop and …
WEBArcturus will bring its mRNA design and modification expertise, LUNAR® lipid nanoparticle (LNP) technology and manufacturing know-how, which has enabled the Company’s low dose, lyophilized and durable self-amplifying mRNA vaccines against COVID-19.
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non …
WEBDec 21, 2023 · Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza.
Arcturus Therapeutics is a global late-stage clinical messenger …
WEBArcturus Therapeutics is a global messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines.
- Some results have been removed